Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | USP19 | O94966 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140934 | 0.88 | TLR7 (0.34) | TLR7USP19CDK1CYP3A4ALOX15 | |
| SCHEMBL1140965 | 0.81 | TLR8 (0.32) | TLR7TLR8NUDT1PDE5A | |
| SCHEMBL1141156 | 0.78 | TLR7 (0.39) | TLR7TLR8NUDT1 | |
| SCHEMBL1141292 | 0.75 | TLR7 (0.40) | TLR7TLR8NUDT1 | |
| SCHEMBL1140585 | 0.72 | TLR7 (0.64) | TLR7TLR8NUDT1 | |
| SCHEMBL4301280 | 0.72 | AKT1 (0.41) | TLR7TLR8NUDT1PDE5A | |
| SCHEMBL1140391 | 0.71 | TLR7 (0.66) | TLR7TLR8NUDT1 | |
| SCHEMBL6098457 | 0.70 | TLR8 (0.42) | TLR7TLR8NUDT1PDE5ACYP3A4 | |
| SCHEMBL1140888 | 0.69 | TLR7 (0.66) | TLR7TLR8NUDT1 | |
| SCHEMBL8123629 | 0.69 | TSHR (0.41) | TLR7TLR8CDK1CYP3A4NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2018-08-09 | — | — | US | disclosed |
| US-9938275-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170129891-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2017-05-11 | — | — | US | disclosed |
| US-9550773-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-01-24 | — | — | US | disclosed |
| EP-1765348-B1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20150218162-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2015-08-06 | — | — | US | disclosed |
| US-9006264-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140011777-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-01-09 | — | — | US | disclosed |
| US-8541438-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110092477-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-04-21 | — | — | US | disclosed |
| US-7884207-B2 | such as 4-[(4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-ol, used as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-20070287724-A1 | Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-13 | — | — | US | disclosed |
| EP-1765348-A2 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006028545-A2 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | TLR7 56/4885TLR8 342/4885NUDT1 176/4885 |
| US-20140011777-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | TLR7 56/4885TLR8 342/4885NUDT1 176/4885 |
| US-20070287724-A1 | Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines | IL2, IFNG, IL4 | TLR7 62/4885TLR8 346/4885NUDT1 221/4885 |
| US-20150218162-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | TLR7 56/4885TLR8 342/4885NUDT1 176/4885 |
| US-20110092477-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | TLR7 56/4885TLR8 342/4885NUDT1 176/4885 |
| US-20170129891-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | TLR7 56/4885TLR8 342/4885NUDT1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.